Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal 736101, India.
Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 637551, Singapore.
Int J Nanomedicine. 2020 Nov 23;15:9301-9315. doi: 10.2147/IJN.S280976. eCollection 2020.
Since the identification of the first human coronavirus in the 1960s, a total of six coronaviruses that are known to affect humans have been identified: 229E, OC43, severe acute respiratory syndrome coronavirus (SARS-CoV), NL63, HKU1, and Middle East respiratory syndrome coronavirus (MERS-CoV). Presently, the human world is affected by a novel version of the coronavirus family known as SARS-CoV-2, which has an extremely high contagion rate. Although the infection fatality rate (IFR) of this rapidly spreading virus is not high (ranging from 0.00% to 1.54% across 51 different locations), the increasing number of infections and deaths has created a worldwide pandemic situation. To provide therapy to severely infected patients, instant therapeutic support is urgently needed and the repurposing of already approved drugs is presently in progress. In this regard, the development of nanoparticles as effective transporters for therapeutic drugs or as alternative medicines is highly encouraged and currently needed. The size range of the viruses is within 60-140 nm, which is slightly larger than the diameters of nanoparticles, making nanomaterials efficacious tools with antiviral properties. Silver-based nanomaterials (AgNMs) demonstrate antimicrobial and disinfectant effects mostly by generating reactive oxygen species (ROS) and are presently considered as a versatile tool for the treatment of COVID-19 patients. Other metal-based nanoparticles have been primarily reported as delivery agents or surface modifying agents, vaccine adjuvant against coronavirus. The present review summarizes and discusses the possible effectiveness of various surface-modified AgNMs against animal coronaviruses and presents a concept for AgNM-based therapeutic treatment of SARS-CoV-2 in the near future.
自 20 世纪 60 年代首次发现人类冠状病毒以来,目前已确定共有 6 种已知会感染人类的冠状病毒:229E、OC43、严重急性呼吸综合征冠状病毒(SARS-CoV)、NL63、HKU1 和中东呼吸综合征冠状病毒(MERS-CoV)。目前,人类世界正受到一种新型冠状病毒家族的影响,即 SARS-CoV-2,其具有极高的传染性。虽然这种快速传播的病毒的感染死亡率(IFR)并不高(在 51 个不同地点的范围为 0.00%至 1.54%),但感染人数和死亡人数的不断增加已导致全球大流行。为了为重症感染者提供治疗,迫切需要即时的治疗支持,目前正在对已批准的药物进行重新利用。在这方面,开发纳米颗粒作为治疗药物的有效载体或作为替代药物受到高度鼓励且目前非常需要。病毒的尺寸范围在 60-140nm 之间,略大于纳米颗粒的直径,这使得纳米材料成为具有抗病毒特性的有效工具。基于银的纳米材料(AgNMs)主要通过产生活性氧物质(ROS)来表现出抗菌和消毒作用,目前被认为是治疗 COVID-19 患者的多功能工具。其他金属基纳米颗粒主要被报道为递送剂或表面改性剂、冠状病毒疫苗佐剂。本综述总结和讨论了各种表面改性 AgNMs 对动物冠状病毒的可能有效性,并提出了一个在不久的将来基于 AgNM 的 SARS-CoV-2 治疗概念。